World Journal of Nuclear Medicine最新文献_第8页

Initial Experience of 18 F-FET PET-MR Image Fusion for Evaluation of Recurrent Primary Brain Tumors 18f - fet PET-MR影像融合评估复发性原发性脑肿瘤的初步经验

IF 0.6

World Journal of Nuclear Medicine

Pub Date : 2023-09-01 DOI: 10.1055/s-0043-1771282

Habibollah Dadgar, M. S. Vafaee, Amirreza Khorasanchi, Parastoo Kordestani Moghadam, Reza Nemati, Hossein Shooli, Esmail Jafari, Majid Assadi

Abstract Background An accurate monitoring technique is crucial in brain tumors to choose the best treatment approach after surgery and/or chemoradiation. Radiological assessment of brain tumors is widely based on the magnetic resonance imaging (MRI) modality in this regard; however, MRI criteria are unable to precisely differentiate tumoral tissue from treatment-related changes. This study was conducted to evaluate whether fused MRI and O-(2- 18 F-fluoroethyl)-L-tyrosine ( 18 F-FET) positron emission tomography (PET) can improve the diagnostic accuracy of the practitioners to discriminate treatment-related changes from true recurrence of brain tumor. Methods We retrospectively analyzed 18 F-FET PET/computed tomography (CT) of 11 patients with histopathologically proven brain tumors that were suspicious for recurrence changes after 3 to 4 months of surgery. All the patients underwent MRI and 18 F-FET PET/CT. As a third assessment, fused 18 F-FET PET/MRI was also acquired. Finally, the diagnostic accuracy of the applied modalities was compared. Results Eleven patients aged 27 to 73 years with a mean age of 47 ± 13 years were enrolled. According to the results, 9/11 cases (82%) showed positive MRI and 6 cases (55%) showed positive PET/CT and PET/MRI. Tumoral recurrence was observed in six patients (55%) in the follow-up period. Based on the follow-up results, accuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were 64, 85, 25, 67, and 50%, respectively, for MRI alone and 91, 85, 100, 100, and 80%, respectively, for both PET/CT and PET/MRI. Conclusion This study found that 18 F-FET PET-MR image fusion in the management of brain tumors might improve recurrence detection; however, further well-designed studies are needed to verify these preliminary data.

摘要背景准确的监测技术对于脑肿瘤手术和/或放化疗后选择最佳治疗方法至关重要。在这方面，脑肿瘤的放射学评估广泛基于磁共振成像（MRI）模式；然而，MRI标准无法准确区分肿瘤组织和治疗相关的变化。本研究旨在评估融合MRI和O-（2-18F-氟乙基）-L-酪氨酸（18F-FET）正电子发射断层扫描（PET）是否可以提高从业者的诊断准确性，以区分脑肿瘤的治疗相关变化和真实复发。方法我们回顾性分析了11名经组织病理学证实的脑肿瘤患者的18例F-FET PET/计算机断层扫描（CT），这些患者在手术3至4个月后可能出现复发变化。所有患者均行MRI和18F-FET PET/CT检查。作为第三项评估，还采集了融合的18F-FET PET/MRI。最后，比较了应用模式的诊断准确性。后果 11名患者，年龄在27至73岁之间，平均年龄为47岁 ± 入组13年。结果显示，9/11例（82%）MRI阳性，6例（55%）PET/CT和PET/MRI阳性。在随访期间观察到6名患者（55%）出现肿瘤复发。根据随访结果，单独MRI的准确性、敏感性、特异性、阳性预测值（PPV）和阴性预测值（NPV）分别为64%、85%、25%、67%和50%，PET/CT和PET/MRI分别为91%、85%、100%和80%。结论本研究发现，18F-FET PET-MR图像融合在脑肿瘤治疗中可能提高复发检测率；然而，还需要进一步精心设计的研究来验证这些初步数据。

{"title":"Initial Experience of 18 F-FET PET-MR Image Fusion for Evaluation of Recurrent Primary Brain Tumors","authors":"Habibollah Dadgar, M. S. Vafaee, Amirreza Khorasanchi, Parastoo Kordestani Moghadam, Reza Nemati, Hossein Shooli, Esmail Jafari, Majid Assadi","doi":"10.1055/s-0043-1771282","DOIUrl":"https://doi.org/10.1055/s-0043-1771282","url":null,"abstract":"Abstract Background An accurate monitoring technique is crucial in brain tumors to choose the best treatment approach after surgery and/or chemoradiation. Radiological assessment of brain tumors is widely based on the magnetic resonance imaging (MRI) modality in this regard; however, MRI criteria are unable to precisely differentiate tumoral tissue from treatment-related changes. This study was conducted to evaluate whether fused MRI and O-(2- 18 F-fluoroethyl)-L-tyrosine ( 18 F-FET) positron emission tomography (PET) can improve the diagnostic accuracy of the practitioners to discriminate treatment-related changes from true recurrence of brain tumor. Methods We retrospectively analyzed 18 F-FET PET/computed tomography (CT) of 11 patients with histopathologically proven brain tumors that were suspicious for recurrence changes after 3 to 4 months of surgery. All the patients underwent MRI and 18 F-FET PET/CT. As a third assessment, fused 18 F-FET PET/MRI was also acquired. Finally, the diagnostic accuracy of the applied modalities was compared. Results Eleven patients aged 27 to 73 years with a mean age of 47 ± 13 years were enrolled. According to the results, 9/11 cases (82%) showed positive MRI and 6 cases (55%) showed positive PET/CT and PET/MRI. Tumoral recurrence was observed in six patients (55%) in the follow-up period. Based on the follow-up results, accuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were 64, 85, 25, 67, and 50%, respectively, for MRI alone and 91, 85, 100, 100, and 80%, respectively, for both PET/CT and PET/MRI. Conclusion This study found that 18 F-FET PET-MR image fusion in the management of brain tumors might improve recurrence detection; however, further well-designed studies are needed to verify these preliminary data.","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"22 1","pages":"183 - 190"},"PeriodicalIF":0.6,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48191476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neurocognitive Profile and 18 F-Fluorodeoxyglucose Positron Emission Tomography Brain Imaging Correlation in Children with Electrical Status Epilepticus during Sleep 睡眠中癫痫持续电状态儿童的神经认知特征和18f -氟脱氧葡萄糖正电子发射断层扫描脑成像相关性

IF 0.6

World Journal of Nuclear Medicine

Pub Date : 2023-06-27 DOI: 10.1055/s-0042-1757284

Madhur K. Srivastava, Afshan J. Shaik, Sireesha Yareeda, Kavitha Nallapareddy, L. Lingappa, Pallavi Moturi, Padmaja Gaddamonugu, R. M. Kandadai, R. Borgohain

Abstract Objective Electrical status epilepticus in sleep (ESES) is defined by near-continuous epileptiform discharges during sleep along with cognitive, behavioral, and/or imaging abnormalities. We studied the neurocognitive profile and their correlation with 18 F fluorodeoxyglucose positron emission tomography (FDG PET) brain abnormalities in children with ESES. Methods Fourteen children with ESES with normal magnetic resonance imaging (MRI) from March to December 2019 were included. The intelligence quotient (IQ) and child behavior checklist (CBCL) scores were estimated using validated scales, and FDG PET brain was done at the same point of time to look for cerebral metabolic defects which was compared with a control group. Results Fourteen patients with a mean age of 8.2 ± 2.7 years were analyzed. The average duration of epilepsy was 6 ± 2.8 years. The mean IQ was 72.4 ± 18.2 and mean CBCL score was 37.3 ± 11.8. There was negative correlation between IQ and CBCL ( r = −0.55, p < 0.001). The duration of epilepsy also showed negative correlation with IQ ( r = −4.75, p < 0.001). FDG PET scan showed predominant thalamic hypometabolism in 12 of 14 patients (85.7%) on visual analysis with multiple other hypometabolic cortical and subcortical regions in the brain. The quantitative analysis showed significant difference in metabolism of basal ganglion when compared with control group. The total number of hypometabolic regions seen in the brain showed moderate positive correlation with CBCL score but no significant correlation with the IQ of cases. Conclusion This study demonstrates functional impairment of cerebral cortical, basal ganglia, and thalamic hypometabolism in a cohort of ESES patients with normal structural MRI brain study. There was a moderate correlation of extent and pattern of cerebral hypometabolism with the neuropsychological status of the child and duration of epilepsy.

抽象目标睡眠中癫痫持续状态（ESES）是指睡眠中近连续的癫痫样放电以及认知、行为和/或成像异常。我们研究了ESES儿童的神经认知特征及其与18F-氟脱氧葡萄糖正电子发射断层扫描（FDG-PET）大脑异常的相关性。方法纳入了2019年3月至12月14名ESES儿童的正常磁共振成像（MRI）。使用经验证的量表估计智商（IQ）和儿童行为检查表（CBCL）得分，并在同一时间点进行FDG PET大脑检查，以寻找大脑代谢缺陷，并与对照组进行比较。后果 14名患者，平均年龄8.2岁 ± 对2.7年进行了分析。癫痫的平均持续时间为6 ± 2.8年。平均智商为72.4 ± 平均CBCL评分为37.3 ± 11.8.智商与CBCL呈负相关（r = −0.55，p < 癫痫持续时间与IQ呈负相关（r = −4.75，p < 0.001）。FDG PET扫描在视觉分析中显示，14名患者中有12名（85.7%）的丘脑主要低代谢，大脑中有多个其他低代谢皮层和皮层下区域。定量分析显示，与对照组相比，基底神经节的代谢有显著差异。大脑中低代谢区域的总数与CBCL评分呈中度正相关，但与病例的IQ无显著相关性。结论这项研究表明，在一组结构正常的ESES患者中，大脑皮层、基底节和丘脑低代谢的功能受损。大脑低代谢的程度和模式与儿童的神经心理状态和癫痫的持续时间存在中度相关性。

{"title":"Neurocognitive Profile and 18 F-Fluorodeoxyglucose Positron Emission Tomography Brain Imaging Correlation in Children with Electrical Status Epilepticus during Sleep","authors":"Madhur K. Srivastava, Afshan J. Shaik, Sireesha Yareeda, Kavitha Nallapareddy, L. Lingappa, Pallavi Moturi, Padmaja Gaddamonugu, R. M. Kandadai, R. Borgohain","doi":"10.1055/s-0042-1757284","DOIUrl":"https://doi.org/10.1055/s-0042-1757284","url":null,"abstract":"Abstract Objective Electrical status epilepticus in sleep (ESES) is defined by near-continuous epileptiform discharges during sleep along with cognitive, behavioral, and/or imaging abnormalities. We studied the neurocognitive profile and their correlation with 18 F fluorodeoxyglucose positron emission tomography (FDG PET) brain abnormalities in children with ESES. Methods Fourteen children with ESES with normal magnetic resonance imaging (MRI) from March to December 2019 were included. The intelligence quotient (IQ) and child behavior checklist (CBCL) scores were estimated using validated scales, and FDG PET brain was done at the same point of time to look for cerebral metabolic defects which was compared with a control group. Results Fourteen patients with a mean age of 8.2 ± 2.7 years were analyzed. The average duration of epilepsy was 6 ± 2.8 years. The mean IQ was 72.4 ± 18.2 and mean CBCL score was 37.3 ± 11.8. There was negative correlation between IQ and CBCL ( r = −0.55, p < 0.001). The duration of epilepsy also showed negative correlation with IQ ( r = −4.75, p < 0.001). FDG PET scan showed predominant thalamic hypometabolism in 12 of 14 patients (85.7%) on visual analysis with multiple other hypometabolic cortical and subcortical regions in the brain. The quantitative analysis showed significant difference in metabolism of basal ganglion when compared with control group. The total number of hypometabolic regions seen in the brain showed moderate positive correlation with CBCL score but no significant correlation with the IQ of cases. Conclusion This study demonstrates functional impairment of cerebral cortical, basal ganglia, and thalamic hypometabolism in a cohort of ESES patients with normal structural MRI brain study. There was a moderate correlation of extent and pattern of cerebral hypometabolism with the neuropsychological status of the child and duration of epilepsy.","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":0.6,"publicationDate":"2023-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43670682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Screening for Clonal Hematopoiesis for Mitigating the Risk of Hematopoietic Neoplasms after PRRT. 筛选克隆造血以降低PRRT术后造血肿瘤的风险。

IF 0.6

World Journal of Nuclear Medicine

Pub Date : 2023-06-01 DOI: 10.1055/s-0043-1764308

Piyush Chandra, Kishore Kumar

Lu-DOTATATE, a peptide receptor-based radionuclide therapy (PRRT), is one of latest treatment options for patients with progressive gastro-entero-pancreatic neuroendocrine tumors (NETs) and leads to significantly better disease-free survival.1 Although rare, an ominous adverse effect seen with PRRT is development of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Recently, a global multicenter study done by Vigne et al using the World Health Organization pharmacovigilance database VigiBase including 1,674 cases, showed0.91 and0.31% incidence ofMDSandAML, respectively. These adverse events were associated with treatment discontinuation in all affected patients, andmore importantly approximatelyone-third of these cases eventually had fatal outcomes.2 Based on accumulated clinical data over the past decade and a half, incidence of PRRT-relatedmyeloid neoplasms (t-MN) has been reported in 0.2 to 5.4% of the patients.3–6 Long-term follow-up data from Erasmus Medical Centre, including 1,214 patients showed MDS incidence at 1.5% after a median followup of 28 months and acute leukemia at 0.7% after a median follow-up of 55 months after first therapy.7 The final results of theNETTER-1studygroupshowedt-MNriskat1.2%post5years of the last patient is randomized.8 A slightly higher percentage of patients experienced t-MN after PRRT in two other studies, both of which combined PRRT with prior or concomitant chemotherapy. Of note, a much higher rate of t-MN (20%) was reported by Brieau et al in a limited series of 20 nonresectable NETs treated with Lu-PPRT after heavy pretreatment with chemotherapy.9Another studydonebyGoncalves et al from the Peter MacCallum Cancer center including 521 patients over a 12-year period showed 4.8% incidence of t-MN.10 Twenty-five percent of these patients had receivedprior chemotherapywith carboplatin/etoposide and 88% received concomitant radiosensitizing chemotherapy such as 5FU or capecitabine. Themedian overall survival (OS) after diagnosis of t-MN was shown to be mere 13 months. Although the novel approach of PRRT with combined chemotherapy may potentially offer better tumor control, it may also slightly augment the risk of t-MN. The quest for identifying predictive biomarkers for post-tMN continues. Unlike nephrotoxicitywhich is considered dosedependent side effect of PRRT, occurrence of long-term hematological toxicity is difficult to predict based onmarrow dosimetryalone.11AstudydonebyBrieauetal showedtwoprognostic factors for the development of t-MN identified in this study: (1) early grade 3 to 4 hematological toxicity after PRRT and (2) higher number of chemotherapy cycles before PRRT. Similarly, post-PRRT thrombocytopenia was significantly related to the development of secondary MDS or AML in a previous study.5 Hence, close monitoring should be recommended in patients experiencing early hematological toxicity after PRRT. A novel strategy to mitigate the risk of t-MN appears to be pretreatment identificat

{"title":"Screening for Clonal Hematopoiesis for Mitigating the Risk of Hematopoietic Neoplasms after PRRT.","authors":"Piyush Chandra, Kishore Kumar","doi":"10.1055/s-0043-1764308","DOIUrl":"https://doi.org/10.1055/s-0043-1764308","url":null,"abstract":"Lu-DOTATATE, a peptide receptor-based radionuclide therapy (PRRT), is one of latest treatment options for patients with progressive gastro-entero-pancreatic neuroendocrine tumors (NETs) and leads to significantly better disease-free survival.1 Although rare, an ominous adverse effect seen with PRRT is development of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Recently, a global multicenter study done by Vigne et al using the World Health Organization pharmacovigilance database VigiBase including 1,674 cases, showed0.91 and0.31% incidence ofMDSandAML, respectively. These adverse events were associated with treatment discontinuation in all affected patients, andmore importantly approximatelyone-third of these cases eventually had fatal outcomes.2 Based on accumulated clinical data over the past decade and a half, incidence of PRRT-relatedmyeloid neoplasms (t-MN) has been reported in 0.2 to 5.4% of the patients.3–6 Long-term follow-up data from Erasmus Medical Centre, including 1,214 patients showed MDS incidence at 1.5% after a median followup of 28 months and acute leukemia at 0.7% after a median follow-up of 55 months after first therapy.7 The final results of theNETTER-1studygroupshowedt-MNriskat1.2%post5years of the last patient is randomized.8 A slightly higher percentage of patients experienced t-MN after PRRT in two other studies, both of which combined PRRT with prior or concomitant chemotherapy. Of note, a much higher rate of t-MN (20%) was reported by Brieau et al in a limited series of 20 nonresectable NETs treated with Lu-PPRT after heavy pretreatment with chemotherapy.9Another studydonebyGoncalves et al from the Peter MacCallum Cancer center including 521 patients over a 12-year period showed 4.8% incidence of t-MN.10 Twenty-five percent of these patients had receivedprior chemotherapywith carboplatin/etoposide and 88% received concomitant radiosensitizing chemotherapy such as 5FU or capecitabine. Themedian overall survival (OS) after diagnosis of t-MN was shown to be mere 13 months. Although the novel approach of PRRT with combined chemotherapy may potentially offer better tumor control, it may also slightly augment the risk of t-MN. The quest for identifying predictive biomarkers for post-tMN continues. Unlike nephrotoxicitywhich is considered dosedependent side effect of PRRT, occurrence of long-term hematological toxicity is difficult to predict based onmarrow dosimetryalone.11AstudydonebyBrieauetal showedtwoprognostic factors for the development of t-MN identified in this study: (1) early grade 3 to 4 hematological toxicity after PRRT and (2) higher number of chemotherapy cycles before PRRT. Similarly, post-PRRT thrombocytopenia was significantly related to the development of secondary MDS or AML in a previous study.5 Hence, close monitoring should be recommended in patients experiencing early hematological toxicity after PRRT. A novel strategy to mitigate the risk of t-MN appears to be pretreatment identificat","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"22 2","pages":"150-151"},"PeriodicalIF":0.6,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202583/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9888128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rare Isolated Cerebellar Metastases in Prostate Cancer: A Case Report with Review of Literature. 罕见孤立性前列腺癌小脑转移1例并文献复习。

IF 0.6

World Journal of Nuclear Medicine

Pub Date : 2023-06-01 DOI: 10.1055/s-0043-1768449

Nimmagadda Ajit, Gadepalli Tejonath, Bikkina Pratyusha, Abubacker Ali Zakir

Prostate cancer is a common malignancy affecting elderly males. Generally, prostate cancer metastases to lymph nodes and skeletal lesions. Brain metastasis from prostate cancer is an uncommon phenomenon. When occurs, it affects the liver and lungs. Less than 1% of the cases show brain metastases, with isolated brain metastases being even more rare. We present the case of a 67-year-old male patient who was diagnosed to have prostate carcinoma and maintained on hormonal therapy. Later, the patient presented with raising serum-68 prostate-specific antigen (PSA) levels. Gallium-68 prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) scan revealed isolated cerebellar metastasis. He was later treated with whole brain radiotherapy.

前列腺癌是影响老年男性的常见恶性肿瘤。一般来说，前列腺癌转移到淋巴结和骨骼病变。前列腺癌脑转移是一种罕见的现象。当它发生时，会影响肝脏和肺部。不到1%的病例表现为脑转移，孤立的脑转移更为罕见。我们提出的情况下，一个67岁的男性患者被诊断为前列腺癌和维持激素治疗。随后，患者出现血清-68前列腺特异性抗原(PSA)水平升高。镓-68前列腺特异性膜抗原(PSMA)正电子发射断层扫描(PET)/计算机断层扫描(CT)显示孤立的小脑转移。他后来接受了全脑放射治疗。

引用次数: 0

Sellar-Parasellar and Petrous Bone Metastasis from Differentiated Thyroid Carcinoma: Imaging Characteristics and Follow-Up Profile Post Radioiodine Therapy. 分化型甲状腺癌鞍-鞍旁和岩状骨转移:放射碘治疗后的影像学特征和随访资料。

IF 0.6

World Journal of Nuclear Medicine

Pub Date : 2023-06-01 DOI: 10.1055/s-0043-1768664

Sunita Nitin Sonavane, Trupti Upadhye, Sandip Basu

Sella turcica and petrous bone metastasis from differentiated thyroid carcinoma are rare clinical entities, with only a few limited cases reported to date. Two cases, one of sella turcica metastasis and the other of petrous bone metastasis from carcinoma of the thyroid gland, are presented. The cases diagnosed to have arisen from poorly differentiated thyroid carcinoma and follicular carcinoma of thyroid, respectively, subsequently underwent total thyroidectomy, radioiodine (RAI) scans and RAI therapies with iodine-131, external radiotherapy, and levothyroxine suppression with follow-up. Their clinical symptoms gradually subsided, with reduction in serum thyroglobulin, and finally resulted in disease stabilization. With the multimodality therapeutic approach, both patients are alive to date, with 48- and 60-month survival post diagnosis, respectively.

分化型甲状腺癌的蝶鞍和岩样骨转移是罕见的临床病例，迄今只有少数有限的病例报道。本文报告2例甲状腺癌的蝶鞍转移及石质骨转移。诊断为低分化甲状腺癌和甲状腺滤泡癌的病例，分别行甲状腺全切除术、放射性碘(RAI)扫描和碘-131、外放疗、左旋甲状腺素抑制的RAI治疗。临床症状逐渐消退，血清甲状腺球蛋白降低，最终病情稳定。采用多模式治疗方法，两名患者至今均存活，诊断后分别存活48个月和60个月。

引用次数: 0

Impact of Region-of-Interest Delineation on Stability and Reproducibility of Liver SNR Measurements in ⁶⁸ Ga-PSMA PET/CT. 兴趣区域划定对68 Ga-PSMA PET/CT肝脏信噪比测量的稳定性和可重复性的影响。

IF 0.6

World Journal of Nuclear Medicine

Pub Date : 2023-06-01 DOI: 10.1055/s-0043-1768446

Masoomeh Fooladi, Sahar Rezaei, Farahnaz Aghahosseini, Yalda Salehi, Nima Kasraie, Peyman Sheikhzadeh

Objective This study aims to assess the impact of various regions of interest (ROIs) and volumes of interest (VOIs) delineations on the reproducibility of liver signal-to-noise-ratio (SNRliver) measurements, as well as to find the most reproducible way to estimate it in gallium-68 positron emission tomography ( ⁶⁸ Ga-PET) imaging. We also investigated the SNRliver-weight relationship for these ROIs and VOIs delineations. Methods A cohort of 40 patients (40 males; mean weight: 76.5 kg [58-115 kg]) with prostate cancer were included. ⁶⁸ Ga-PET/CT imaging (mean injected activity: 91.4 MBq [51.2 MBq to 134.1 MBq] was performed on a 5-ring bismuth germanium oxide-based Discovery IQ PET/CT using ordered subset expectation maximization image reconstruction algorithm. Afterward, circular ROIs and spherical VOIs with two different diameters of 30 and 40 mm were drawn on the right lobe of the livers. The performance of the various defined regions was evaluated by the average standardized uptake value (SUV _mean ), standard deviation (SD) of the SUV (SUV _SD ), SNR _liver , and SD of the SNR _liver metrics. Results There were no significant differences in SUV _mean among the various ROIs and VOIs ( p > 0.05). On the other hand, the lower SUV _SD was obtained by spherical VOI with diameter of 30 mm. The largest SNR _liver was obtained by ROI (30 mm). The SD of SNR _liver with ROI (30 mm) was also the largest, while the lowest SD of SNR _liver was observed for VOI (40 mm). There is a higher correlation coefficient between the patient-dependent parameter of weight and the image quality parameter of SNRliver for both VOI (30 mm) and VOI (40 mm) compared to the ROIs. Conclusion Our results indicate that SNR _liver measurements are affected by the size and shape of the respective ROIs and VOIs. The spherical VOI with a 40 mm diameter leads to more stable and reproducible SNR measurement in the liver.

目的本研究旨在评估不同感兴趣区域(roi)和感兴趣体积(VOIs)描绘对肝脏信噪比(SNRliver)测量再现性的影响，并寻找在镓-68正电子发射断层扫描(68 Ga-PET)成像中最具再现性的估计方法。我们还研究了这些roi和voi圈定的snriver -weight关系。方法选取40例患者(男性40例;平均体重:76.5 kg [58-115 kg])，伴有前列腺癌。采用有序子集期望最大化图像重建算法，在5环氧化铋锗基Discovery IQ PET/CT上进行68 Ga-PET/CT成像(平均注入活度:91.4 MBq [51.2 ~ 134.1 MBq])。然后在肝右叶绘制直径分别为30和40 mm的圆形roi和球形voi。通过平均标准化摄取值(SUV mean)、SUV的标准差(SD)、信噪比肝和信噪比肝指标的SD来评估各个定义区域的性能。结果不同roi和voi的SUV均值比较，差异均无统计学意义(p > 0.05)。另一方面，通过直径为30 mm的球形VOI获得较低的SUV SD。ROI获得最大信噪比肝(30 mm)。ROI组(30 mm)肝的信噪比SD最大，VOI组(40 mm)肝的信噪比SD最低。与roi相比，VOI (30 mm)和VOI (40 mm)的患者相关权重参数与snliver的图像质量参数之间的相关系数更高。结论肝的信噪比测量结果受roi和voi的大小和形状的影响。直径为40 mm的球形VOI可在肝脏中实现更稳定和可重复的信噪比测量。

{"title":"Impact of Region-of-Interest Delineation on Stability and Reproducibility of Liver SNR Measurements in 68 Ga-PSMA PET/CT.","authors":"Masoomeh Fooladi, Sahar Rezaei, Farahnaz Aghahosseini, Yalda Salehi, Nima Kasraie, Peyman Sheikhzadeh","doi":"10.1055/s-0043-1768446","DOIUrl":"https://doi.org/10.1055/s-0043-1768446","url":null,"abstract":"Objective This study aims to assess the impact of various regions of interest (ROIs) and volumes of interest (VOIs) delineations on the reproducibility of liver signal-to-noise-ratio (SNRliver) measurements, as well as to find the most reproducible way to estimate it in gallium-68 positron emission tomography ( 68 Ga-PET) imaging. We also investigated the SNRliver-weight relationship for these ROIs and VOIs delineations. Methods A cohort of 40 patients (40 males; mean weight: 76.5 kg [58-115 kg]) with prostate cancer were included. 68 Ga-PET/CT imaging (mean injected activity: 91.4 MBq [51.2 MBq to 134.1 MBq] was performed on a 5-ring bismuth germanium oxide-based Discovery IQ PET/CT using ordered subset expectation maximization image reconstruction algorithm. Afterward, circular ROIs and spherical VOIs with two different diameters of 30 and 40 mm were drawn on the right lobe of the livers. The performance of the various defined regions was evaluated by the average standardized uptake value (SUV mean ), standard deviation (SD) of the SUV (SUV SD ), SNR liver , and SD of the SNR liver metrics. Results There were no significant differences in SUV mean among the various ROIs and VOIs ( p > 0.05). On the other hand, the lower SUV SD was obtained by spherical VOI with diameter of 30 mm. The largest SNR liver was obtained by ROI (30 mm). The SD of SNR liver with ROI (30 mm) was also the largest, while the lowest SD of SNR liver was observed for VOI (40 mm). There is a higher correlation coefficient between the patient-dependent parameter of weight and the image quality parameter of SNRliver for both VOI (30 mm) and VOI (40 mm) compared to the ROIs. Conclusion Our results indicate that SNR liver measurements are affected by the size and shape of the respective ROIs and VOIs. The spherical VOI with a 40 mm diameter leads to more stable and reproducible SNR measurement in the liver.","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"22 2","pages":"124-129"},"PeriodicalIF":0.6,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202577/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9888126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lesion Analysis in PERCIST 1.0: Clinical Ease versus Research Requisite-Where Does the Balance Exist? perist 1.0中的病变分析:临床方便与研究需要——平衡在哪里?

IF 0.6

World Journal of Nuclear Medicine

Pub Date : 2023-06-01 DOI: 10.1055/s-0042-1750406

Amit Bhoil

Background Semiqualitative parameter SUVmax has been the most frequently used semiquantitative positron emission tomography (PET) parameter for response evaluation, but only metabolic activity of a single (most metabolic) lesion is predicted. Newer response parameters such as tumor lesion glycolysis (TLG) incorporating lesions' metabolic volume or whole-body metabolic tumor burden (MTBwb) are being explored for response evaluation. Evaluation and comparison of response with different semiquantitative PET parameters such as SUVmax and TLG in most metabolic lesion, multiple lesions (max of five), and MTBwb in advanced non-small cell lung cancer (NSCLC) patients were made. The different PET parameters were analyzed for response evaluation, overall survival (OS), and progression-free survival (PFS). Methods ¹⁸ F-FDG-PET/CT (18-fluorine-fluorodeoxyglucose positron emission tomography/computed tomography) imaging was performed in 23 patients (M = 14, F = 9, mean age = 57.6 years) with stage IIIB-IV advanced NSCLC before initiation of therapy with oral estimated glomerular filtration rate-tyrosine kinase inhibitor for early and late response evaluation. The quantitative PET parameters such as SUVmax and TLG were measured in single (most metabolic) lesion, multiple lesions, and MTBwb. The parameters SUVmax, TLG, and MTBwb were compared for early and late response evaluation and analyzed for OS and PFS Results No significant difference in change in response evaluation was seen in patients evaluated with most metabolic lesion, multiple lesions, or MTBwb. Difference in early (DC 22, NDC 1) and late (DC 20, NDC 3) response evaluation was seen that remained unchanged when lesions were measured in terms of number of lesions or the MTBwb. The early imaging was seen to be statistically significant to the OS compared with late imaging. Conclusions Single (most metabolic) lesion shows similar disease response and OS to multiple lesions and MTBwb. Response evaluation by late imaging offered no significant advantage compared with early imaging. Thus, early response evaluation with SUVmax parameter offers a good balance between clinical ease and research requisition.

半定性参数SUVmax一直是评价反应最常用的半定量正电子发射断层扫描(PET)参数，但只能预测单个(大部分代谢)病变的代谢活性。新的反应参数，如肿瘤病变糖酵解(TLG)，结合病变的代谢体积或全身代谢肿瘤负荷(MTBwb)，正在探索用于反应评估。对晚期非小细胞肺癌(NSCLC)患者的大部分代谢性病变、多发病变(最大为5个)、MTBwb等不同半定量PET参数的疗效进行评价和比较。对不同PET参数进行分析，以评估疗效、总生存期(OS)和无进展生存期(PFS)。方法对23例IIIB-IV期晚期非小细胞肺癌患者(M = 14, F = 9，平均年龄57.6岁)进行18 F- fdg - pet /CT(18-氟-氟氧葡萄糖正电子发射断层扫描/计算机断层扫描)成像，并在口服肾小球滤过率-酪氨酸激酶抑制剂治疗前进行早期和晚期疗效评估。定量PET参数如SUVmax和TLG在单个(最代谢)病变，多发病变和MTBwb测量。比较SUVmax、TLG和MTBwb参数进行早期和晚期反应评估，并分析OS和PFS。结果在大多数代谢性病变、多发病变或MTBwb评估的患者中，反应评估的变化无显著差异。早期(DC 22, NDC 1)和晚期(DC 20, NDC 3)反应评价的差异在以病变数量或MTBwb测量病变时保持不变。与晚期影像学相比，早期影像学对OS有统计学意义。结论单发病变(多数为代谢性病变)与多发病变及MTBwb的疾病反应和OS相似。晚期影像学反应评价与早期影像学比较无明显优势。因此，用SUVmax参数进行早期反应评价，在临床简易性和研究需求之间取得了很好的平衡。

{"title":"Lesion Analysis in PERCIST 1.0: Clinical Ease versus Research Requisite-Where Does the Balance Exist?","authors":"Amit Bhoil","doi":"10.1055/s-0042-1750406","DOIUrl":"https://doi.org/10.1055/s-0042-1750406","url":null,"abstract":"Background Semiqualitative parameter SUVmax has been the most frequently used semiquantitative positron emission tomography (PET) parameter for response evaluation, but only metabolic activity of a single (most metabolic) lesion is predicted. Newer response parameters such as tumor lesion glycolysis (TLG) incorporating lesions' metabolic volume or whole-body metabolic tumor burden (MTBwb) are being explored for response evaluation. Evaluation and comparison of response with different semiquantitative PET parameters such as SUVmax and TLG in most metabolic lesion, multiple lesions (max of five), and MTBwb in advanced non-small cell lung cancer (NSCLC) patients were made. The different PET parameters were analyzed for response evaluation, overall survival (OS), and progression-free survival (PFS). Methods 18 F-FDG-PET/CT (18-fluorine-fluorodeoxyglucose positron emission tomography/computed tomography) imaging was performed in 23 patients (M = 14, F = 9, mean age = 57.6 years) with stage IIIB-IV advanced NSCLC before initiation of therapy with oral estimated glomerular filtration rate-tyrosine kinase inhibitor for early and late response evaluation. The quantitative PET parameters such as SUVmax and TLG were measured in single (most metabolic) lesion, multiple lesions, and MTBwb. The parameters SUVmax, TLG, and MTBwb were compared for early and late response evaluation and analyzed for OS and PFS Results No significant difference in change in response evaluation was seen in patients evaluated with most metabolic lesion, multiple lesions, or MTBwb. Difference in early (DC 22, NDC 1) and late (DC 20, NDC 3) response evaluation was seen that remained unchanged when lesions were measured in terms of number of lesions or the MTBwb. The early imaging was seen to be statistically significant to the OS compared with late imaging. Conclusions Single (most metabolic) lesion shows similar disease response and OS to multiple lesions and MTBwb. Response evaluation by late imaging offered no significant advantage compared with early imaging. Thus, early response evaluation with SUVmax parameter offers a good balance between clinical ease and research requisition.","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"22 2","pages":"100-107"},"PeriodicalIF":0.6,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202569/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9570002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Post-Topotecan Mixed Response and 'Redifferentiation-akin' Phenomenon on Dual Tracer PET-CT in Multiple Treatment-Resistant Metastatic Neuroendocrine Neoplasm. 双示踪PET-CT对多发性治疗耐药转移性神经内分泌肿瘤的拓扑替康后混合反应和“类似再分化”现象

IF 0.6

World Journal of Nuclear Medicine

Pub Date : 2023-06-01 DOI: 10.1055/s-0043-1760761

Sarvesh Loharkar, Sandip Basu

A 50-year-old female patient of heavily pre-treated (chemotherapy and multiple treatment-resistant) and progressive intermediate-grade metastatic neuroendocrine neoplasm is presented, wherein the lesions showed mixed response following topotecan treatment and multiple hepatic metastasis showed increase in the SSTR expression and decrease in FDG concentration on dual-tracer PET/CT ( ⁶⁸ Ga-DOTATATE and ¹⁸ F-FDG PET/CT). Such observation allowed ¹⁷⁷ Lu-DOTATATE PRRT to be considered for an advanced, symptomatic, and multiple treatment-resistant patient with limited palliative treatment options left.

本文报道一名50岁女性患者，重度预处理(化疗和多重治疗耐药)，进展中转移性神经内分泌肿瘤，拓扑替康治疗后病变表现为混合反应，多发肝转移，双示踪PET/CT (68 Ga-DOTATATE和18 F-FDG PET/CT)显示SSTR表达增加，FDG浓度降低。这样的观察结果使得177 Lu-DOTATATE PRRT被考虑用于晚期、有症状且多重治疗耐药的患者，这些患者只剩下有限的姑息治疗选择。

引用次数: 0

Assessment of Pulmonary Metastasis in Differentiated Thyroid Carcinoma: Value of HRCT Correlation with Functional Imaging. 分化型甲状腺癌肺转移的评价:HRCT与功能影像学的相关性。

IF 0.6

World Journal of Nuclear Medicine

Pub Date : 2023-06-01 DOI: 10.1055/s-0043-1764307

Ashwini Kalshetty, Sandip Basu

Pulmonary metastases in thyroid carcinoma demonstrates varying imaging characteristics and disease biology and the outcome. The valuable complimentary role of high-resolution CT (HRCT) in conjunction with functional imaging such as radioiodine scan has been discussed and illustrated in this review along with the varied clinical and imaging presentations of lung metastases from differentiated thyroid cancer (DTC). A multi-modality patient-specific diagnostic approach and awareness about the atypical presentations helps in early identification as well as effective management of these patients, and especially in certain situations that could need multi-disciplinary management. While HRCT of the lungs as an added tool provides detailed visualization of the lung parenchyma, in the era of hybrid imaging, the routine adoption of SPECT-CT in patients with pulmonary metastases (in diagnostic or post-treatment settings) could provide equivalent or even incremental information from further management viewpoint.

甲状腺癌肺转移表现出不同的影像学特征、疾病生物学和预后。本文讨论了高分辨率CT (HRCT)与放射性碘扫描等功能成像相结合的宝贵互补作用，并阐述了分化型甲状腺癌(DTC)肺转移的不同临床和影像学表现。多模式的患者特异性诊断方法和对非典型表现的认识有助于早期识别和有效管理这些患者，特别是在某些可能需要多学科管理的情况下。虽然肺部HRCT作为一种附加工具提供了肺实质的详细可视化，但在混合成像时代，肺转移患者(在诊断或治疗后设置)常规采用SPECT-CT可以从进一步的管理角度提供等效甚至增量的信息。

引用次数: 0

Nuclear Medicine Training: Skills and Competencies Required for Practice in the 21st Century. 核医学培训:21世纪实践所需的技能和能力。

IF 0.6

World Journal of Nuclear Medicine

Pub Date : 2023-06-01 DOI: 10.1055/s-0043-1769588

Ismaheel O Lawal

Nuclear medicine (NM) utilizes unsealed radiation sources to diagnose and treat diseases. In the NM team, the NM physician works in collaboration with many other NM professionals who play critical roles in care delivery to patients. The NM team, therefore, consists of the NM physicians, the radiochemists, the medical physicists, and NM technologists, and others. Each of these groups in the NM team has made signi ﬁ cant contributions to the ﬁ eld of NM, resulting in amazing growth over thelast two decades or so. 1 Thisgrowth with implications for a promising feature for NM has been in the form of improvement in instrumentation, advances in radiopharmaceutical synthesis, the introduction of novel diagnostic and therapeutic radiopharmaceuticals, optimiza-tion of dosimetry methods, and, consequently, broadening of the applications of NM techniques in the clinics. While this growth occurring in all aspects of the ﬁ eld has made the future of the profession exciting, it has also come with a need for residency training to evolve to produce NM physicians with the requisite skill sets and competencies that make them suitable to deliver ef ﬁ cient care in the 21st century. In this editorial, I will focus on the emerging skill sets and competencies that NM trainees need to acquire in their residency training to render ﬁ t-for-purpose diagnostic and therapeutic NM care in the 21st century.

{"title":"Nuclear Medicine Training: Skills and Competencies Required for Practice in the 21st Century.","authors":"Ismaheel O Lawal","doi":"10.1055/s-0043-1769588","DOIUrl":"https://doi.org/10.1055/s-0043-1769588","url":null,"abstract":"Nuclear medicine (NM) utilizes unsealed radiation sources to diagnose and treat diseases. In the NM team, the NM physician works in collaboration with many other NM professionals who play critical roles in care delivery to patients. The NM team, therefore, consists of the NM physicians, the radiochemists, the medical physicists, and NM technologists, and others. Each of these groups in the NM team has made signi ﬁ cant contributions to the ﬁ eld of NM, resulting in amazing growth over thelast two decades or so. 1 Thisgrowth with implications for a promising feature for NM has been in the form of improvement in instrumentation, advances in radiopharmaceutical synthesis, the introduction of novel diagnostic and therapeutic radiopharmaceuticals, optimiza-tion of dosimetry methods, and, consequently, broadening of the applications of NM techniques in the clinics. While this growth occurring in all aspects of the ﬁ eld has made the future of the profession exciting, it has also come with a need for residency training to evolve to produce NM physicians with the requisite skill sets and competencies that make them suitable to deliver ef ﬁ cient care in the 21st century. In this editorial, I will focus on the emerging skill sets and competencies that NM trainees need to acquire in their residency training to render ﬁ t-for-purpose diagnostic and therapeutic NM care in the 21st century.","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"22 2","pages":"75-77"},"PeriodicalIF":0.6,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202562/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9871529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0